Cardio3 BioSciences Raises EUR13.7 Million in Series B Fundraising and Grant Funding
- New Funds to Drive Clinical Development of C-Cure(R), a Second-Generation Cell-Based Therapy for Heart Failure
Cardio3 BioSciences, a leading Belgian biotechnology company specialising
in cell-based therapies for the treatment of cardiovascular diseases, has
Cardio3 BioSciences was founded in 2007 by clinicians from the
Cardiovascular Center in Aalst,
In parallel with this equity fund raising Cardio3 BioSciences has raised
C-Cure is a second-generation cell therapy for the treatment of heart failure and draws on an unrivalled understanding of the fundamental science of heart cell development at Mayo Clinic and within the Cardio3 BioSciences scientific in-house team. The product involves taking a patient's own bone marrow cells and through a proprietary culturing technology, gives rise to 'cardiopoietic' cells that can regenerate damaged heart muscle. Unlike previous cell therapies for this indication, C-Cure is designed to produce new autologous heart muscle cells which behave identically to those lost in infarction without carrying the risk of rejection.
The urgent need for a product like C-Cure to improve the treatment of
heart failure is evidenced by the fact that its clinical development is being
guided by some of the leading clinicians in the field in
About Cardio3 BioSciences
Cardio3 BioSciences is a leading Belgian biotechnology company specialising in stem cell-based therapies for the treatment of cardiovascular disease. The Company's lead product, C-Cure is a highly innovative approach to the treatment of heart failure, one of the world's most pressing unmet medical needs. Based on a strategy developed by Cardio3 BioSciences' founders and leveraging technology from Mayo Clinic, C-Cure allows the differentiation of a patient's own cells into 'cardiopoeitic' cells which grow into new heart cells and repair heart muscle. An international clinical trial of C-Cure sponsored by Cardio3 BioSciences is expected to begin in early 2009.
The Cardio3 BioSciences team has extensive experience in developing and commercialising new pharmaceutical products and medical technologies and the Company's strategy is to drive the clinical development of C-Cure and to market the product itself in major territories.
Cardio3 BioSciences was founded in
C-Cure is a second generation cell therapy for the treatment of heart failure that involves taking a patient's own stem cells from bone marrow and through a proprietary culturing technology generating differentiated 'cardiopoeitic' cells which can regenerate damaged heart muscle. Unlike previous cell therapies for this indication, C-Cure is designed to produce new autologous heart muscle cells which behave identically to those lost in infarction without carrying the risk of rejection.
C-Cure draws on the unrivalled understanding of the fundamental science of heart cell development within Cardio3 BioSciences and on technology developed at Mayo Clinic, one of the world's best respected medical research centres.
C-Cure is expected to enter an international clinical trial early in
2009. The potential of the product is reflected in the fact that its
development is being guided by some of the leading clinicians in the field in
For more information contact: Cardio3 BioSciences Dr Christian Homsy, CEO Tel: +32-10-39-41-00 email@example.com Mayra Beydoun, Brand & Communication Manager Tel : +32-10-39-41-00 firstname.lastname@example.org http://www.c3bs.com Citigate Dewe Rogerson Chris Gardner/Heather Keohane/Nina Enegren Tel : +44(0)207-638-9571 email@example.com
SOURCE Cardio3 BioSciences
More by this Source
Cardio3 BioSciences Partner and Exploitation Manager of a Eur 4.5 Million FP7 Research Grant
Nov 25, 2013, 05:49 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.